Autopsy report · NCT00632827
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Cause of deathDrug or device supply
“Manufacturing shortage of both Diftitox and Doxil”
Life of this trial
- Registered 4 months before it started.
- Ran for about 8 years before it stopped.
- 21 participants enrolled.
- Results were posted on the registry 3 years 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Conditions
- Peripheral T-Cell Lymphoma
- Interventions
- Gemcitabine; Navelbine; Doxorubicin Hydrochloride Liposome Injection; Granulocyte-colony stimulating factor (G-CSF); Pegfilgrastim; Cyclophosphamide
- Participants
- 21
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.